JP2019514950A5 - - Google Patents

Description

Both the foregoing summary and the following detailed description are exemplary and explanatory only,
It should be understood that it is not intended to limit the claimed invention.
In the embodiment of the present invention, for example, the following items are provided.
(Item 1)
A compound having formula I, or a pharmaceutically acceptable salt, hydrate or solvate thereof:

In the formula,

Is a fused thienyl or fused phenyl group,
G is the following:

Selected from the group consisting of;
W ¹ Does not exist or -CH ₂ -Is;
Z ¹ Is -C(R)(-E ¹ -R ^4a )-, -N(-E ¹ -R ^4a )- and -C[-N(-E ² -R ^4b )(R ^4h )](R ^5a )-Selected from the group consisting of;
W ² Does not exist or -CH ₂ -Is;
Z ² Is -N(-E ³ -R ^4c )- and -C[-N(-E ^Four -R ^4d )(R ⁴ⁱ )](R ^5b )-Selected from the group consisting of;
W ³ Does not exist or -CH ₂ -Is;
Z ³ Is -N(-E ^Five -R ^4e )- and -C[-N(-E ⁶ -R ^4f )(R ^4j )](R ^5c )-Selected from the group consisting of;

Is a single bond or a double bond, provided that

R is a double bond, R ^6h And R ⁶ⁱ Does not exist;
Q ¹ And Q ² Are each independently CH or N;
XY is the following:
-N(R ^1a )-C(=O)-;
-C(=O)-O-;
-C(=O)-N(R ^1b )-;
-CH ₂ N(R ^1c )-CH ₂ -;
-C(=O)N(R ^1d )-CH ₂ -;
-CH ₂ CH ₂ -N(R ^1e )-;
-CH ₂ N(R ^1f )-C(=O)-; and
-CH ₂ O-CH ₂ -
Is selected from the group consisting of; or
X and Y do not form a chemical bond, and
X is selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy; and
Y is cyano, hydroxy, and -CH ₂ -R ¹² Selected from the group consisting of;
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , E ⁷ , E ⁸ , E ⁹ , And E ^Ten Are each independently the following: -C(=O)-;-C(=O)N(R ¹³ )-; -[C(R ^14a )(R ^14b )] _m O-;-[C(R ^14a )(R ^14b )] _m N(R ¹⁵ )-; -[C(R ^14c )(R ^14d )] _n -; -CH ₂ (=O)-; and -S(=O) ₂ -Is selected from the group consisting of; or
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , E ⁷ , E ⁸ , E ⁹ , And E ^Ten Does not exist independently of each other;
R is selected from the group consisting of hydrogen and alkyl;
R ^1a Is selected from the group consisting of hydrogen and alkyl;
R ^1b Is selected from the group consisting of hydrogen, alkyl, and aralkyl;
R ^1c Is hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, (heteroaryl)alkyl, alkylcarbonyl, aryl Carbonyl, and selected from the group consisting of alkoxycarbonyl;
R ^1d Is selected from the group consisting of hydrogen, alkyl, and aralkyl;
R ^1e Is selected from the group consisting of hydrogen, alkyl, and (aryloxy)alkyl;
R ^1f Is selected from the group consisting of hydrogen and alkyl;
R ² Is selected from the group consisting of hydrogen, alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted heteroaryl, and aralkyl. ;
R ^3a And R ^3b Are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , R ^{4 g} , R ^4k , R ^4l , And R ^4m Are each independently hydrogen, alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted. Selected from the group consisting of heterocyclo, optionally substituted heteroaryl, aralkyl, (heterocyclo)alkyl, and (heteroaryl)alkyl;
R ^4h , R ⁴ⁱ , And R ^4j Are each independently selected from the group consisting of hydrogen and alkyl;
R ^5a , R ^5b , R ^5c , And R ^5d Are each independently selected from the group consisting of hydrogen and alkyl;
R ^6a , R ^6b , R ^6c , R ^6d , R ^6e , R ^6f , R ^{6 g} , And R ^6h Are each independently selected from the group consisting of hydrogen and alkyl;
R ⁶ⁱ Is selected from the group consisting of hydrogen, alkyl, and halo;
R ^7a , R ^7b , R ^7c , R ^7d , R ^7e , And R ^7f Are each independently selected from the group consisting of hydrogen and alkyl;
R ^{7 g} Is selected from the group consisting of hydrogen, alkyl, and halo;
R ^8a , R ^8b , R ^8c , And R ^8d Are each independently selected from the group consisting of hydrogen and alkyl;
R ^8e Is selected from the group consisting of hydrogen, alkyl, and halo;
R ^9a And R ^9b Are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ^10a And R ^10b Are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ^11a And R ^11b Are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ¹² Is hydroxy, amino, optionally substituted heteroaryl, optionally substituted heterocyclo, and -NHC(=O)-R ¹⁶ Selected from the group consisting of;
m is 2, 3, 4, or 5
n is 1, 2, 3, 4, or 5;
R ¹³ Is selected from the group consisting of hydrogen and alkyl;
R ^14a And R ^14b Are each independently selected from the group consisting of hydrogen and alkyl;
R ^14c And R ^14d Are each independently selected from the group consisting of hydrogen and alkyl;
R ¹⁵ Is selected from the group consisting of hydrogen and alkyl; and
R ¹⁶ Is selected from the group consisting of alkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl.
(Item 2)
Formula II:

The compound according to item 1, which comprises: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 3)
Formula III:

The compound according to item 1, which comprises: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 4)
The compound according to any one of items 1 to 3, wherein G is G-1, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 5)
4. The compound according to any one of items 1 to 3, wherein G is G-2, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 6)
4. The compound according to any one of items 1 to 3, wherein G is G-3, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 7)
4. The compound according to any one of items 1 to 3, wherein G is G-4, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 8)
The compound according to any one of items 1 to 3, wherein G is G-5, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 9)
4. The compound according to any one of items 1 to 3, wherein G is G-6, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 10)
The compound according to any one of Items 1 to 3, wherein G is G-7, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 11)
W ¹ Or the pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 12)
W ² Or the pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein
(Item 13)
W ³ Or the pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein
(Item 14)

Is a single bond and R ^6a , R ^6b , R ^6c , R ^6d , R ^6e , R ^6f , R ^{6 g} , R ^6h , And R ⁶ⁱ Independently of hydrogen and C _{1 to 3} Item 12. The compound according to item 4 or 11, which is selected from the group consisting of alkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 15)
R ^6a , R ^6b , R ^6c , R ^6d , R ^6e , R ^6f , R ^{6 g} , R ^6h , And R ⁶ⁱ Wherein each is hydrogen, or the pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 16)
R ^7a , R ^7b , R ^7c , R ^7d , R ^7e , R ^7f , And R ^{7 g} Independently of hydrogen and C _{1 to 3} 13. The compound according to item 5 or 12, which is selected from the group consisting of alkyl, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 17)
R ^7a , R ^7b , R ^7c , R ^7d , R ^7e , R ^7f , And R ^{7 g} Wherein each is hydrogen, or the pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 18)
R ^8a , R ^8b , R ^8c , R ^8d , And R ^8e Independently of hydrogen and C _{1 to 3} 14. The compound according to item 6 or 13 selected from the group consisting of alkyl, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 19)
R ^8a , R ^8b , R ^8c , R ^8d , And R ^8e Wherein each is hydrogen, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 20)
G is below:

Selected from the group consisting of ¹ Is N and Q ² Is a compound according to any one of items 1 to 3, selected from the group consisting of CH and N, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 21)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ , -C(=O)-, -C(=O)N(R ¹³ )-,-[C(R ^14a )(R ^14b )] _m O-, -[C(R ^14a )(R ^14b )] _m N(R ¹⁵ )-,-[C(R ^14c )(R ^14d )] _n -, -CH ₂ (=O)-, and -S(=O) ₂ 21. The compound according to any one of items 1 to 3 or 20, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which is selected from the group consisting of:
(Item 22)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ Wherein each is -C(=O)-, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 23)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But -C(=O)N(R ¹³ )-The compound of claim 21, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 24)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But each -[C(R ^14a )(R ^14b )] _m The compound according to item 21, which is O −, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 25)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But each -[C(R ^14a )(R ^14b )] _m N(R ¹⁵ )-The compound of claim 21, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 26)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But each -[C(R ^14c )(R ^14d )] _n 21. The compound according to item 21, which is: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 27)
n is 1 and R ^14c And R ^14d 27. The compound according to item 26, wherein each is hydrogen, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 28)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But each -CH ₂ Item 21. The compound according to Item 21, which is (=O)-, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 29)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ But each is -S(=O) ₂ 21. The compound according to item 21, which is: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 30)
E ¹ , E ² , E ³ , E ^Four , E ^Five , E ⁶ , And E ⁷ 21. The compound according to any one of items 1 to 3 and 20, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein
(Item 31)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} Are each independently alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted heteroaryl, aralkyl, and (heteroaryl) 31. A compound according to any one of items 1-3 and 20-30, or a pharmaceutically acceptable salt, hydrate or solvate thereof, selected from the group consisting of alkyl.
(Item 32)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 32. The compound according to item 31, wherein each is alkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 33)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 32. The compound according to item 31, wherein each is an optionally substituted cycloalkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 34)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 33. The compound according to item 31, wherein each is an optionally substituted aryl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 35)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 33. The compound according to item 31, wherein each is an optionally substituted heterocyclo, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 36)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 33. The compound according to item 31, wherein each is an optionally substituted heteroaryl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 37)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 32. The compound according to item 31, wherein each is aralkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 38)
R ^4a , R ^4b , R ^4c , R ^4d , R ^4e , R ^4f , And R ^{4 g} 32. A compound according to item 31, wherein each is (heteroaryl)alkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 39)
Formula IV:

The compound according to item 1, which comprises: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 40)
E ¹ が-[C(R ^14a )(R ^14b )] _m O- and R ^4a Is a compound selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. .
(Item 41)
A compound according to item 40 having formula V, or a pharmaceutically acceptable salt, hydrate or solvate thereof:

In the formula,
R ^16a Is hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, (cycloalkyl)alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl. , Heterocyclosulfonyl, sulfonamide, optionally substituted heteroaryl, optionally substituted heterocyclo, carboxamide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, carboxy, and carboxyalkyl;
R ^16b Is selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy.
(Item 42)
E ¹ But -C(R ^14c )(R ^14d ) _n -And R ^4a Is replaced by C _{4 ~ 6} 40. The compound according to item 39, which is heterocyclo, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 43)
n is 1 and R ^14c And R ^14d 43. The compound according to item 42, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is hydrogen.
(Item 44)
The compound of item 43, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, having the formula VIi:

In the formula,
R ^17a Is hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, (cycloalkyl)alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl. , Heterocyclosulfonyl, sulfonamide, optionally substituted heteroaryl, optionally substituted heterocyclo, carboxamide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, carboxy, and carboxyalkyl;
R ^17b And R ^17c Are independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy.
(Item 45)
R ^17a Is selected from the group consisting of alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl; and
R ^17b And R ^17c Is hydrogen,
A compound according to item 44, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 46)
R ² Is selected from the group consisting of alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted heteroaryl, and aralkyl, 46. The compound according to any one of items 1 to 45, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 47)
R ² 46. The compound according to item 46, wherein is unsubstituted cycloalkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 48)
R ² 46. The compound according to item 46, wherein is substituted cycloalkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 49)
R ² The compound of item 48, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is a substituted cycloalkyl having the formula VII:

In the formula,
R ¹⁸ Is halo, nitro, cyano, hydroxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamide, sulfonamide, alkylcarbonyl, arylcarbonyl, Alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, substituted Optionally heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, (heterocyclo)alkyl, -OC(=O)-amino, -N(R ^19a )C(=O)-R ^19b , And -N(R ^20a )SO ₂ -R ^20b Selected from the group consisting of;
R ^19a Is selected from the group consisting of hydrogen and alkyl;
R ^19b Is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ^20a Is selected from the group consisting of hydrogen and alkyl;
R ^20b Is selected from the group consisting of amino, alkyl, and optionally substituted aryl.
(Item 50)
R ¹⁸ Is alkylcarbonyloxy, cycloalkylcarbonyloxy, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamide, sulfonamide, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl , Optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, 49. The compound according to item 49, which is selected from the group consisting of (amino)alkyl, (carboxamido)alkyl, and (heterocyclo)alkyl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 51)
R ¹⁸ But -OC(=O)-amino and -NHC(=O)-R ^19b The compound of item 50 selected from the group consisting of: or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 52)
R ² Where the group consisting of:



The compound according to item 46, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which is selected from the formulas above and "*" represents a point of attachment to the rest of the molecule.
(Item 53)
Formula VIII:

The compound according to item 1, which comprises: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 54)
The following formula:

53. The compound according to item 53, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, comprising any one or more of:
(Item 55)
XY is -N(R ^1a )-C(=O)-, -C(=O)-O-, -C(=O)-N(R ^1b )-,-CH ₂ N(R ^1c )-CH ₂ -, -C(=O)N(R ^1d )-CH ₂ -, -CH ₂ CH ₂ -N(R ^1e )-,-CH ₂ N(R ^1f )-C(=O)-, and -CH ₂ O-CH ₂ The compound according to any one of items 1 to 54, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which is selected from the group consisting of:
(Item 56)
XY is -N(R ^1a )-C(=O)-, or a compound thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 57)
The compound of Item 55, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein XY is -C(=O)-O-.
(Item 58)
XY is -C(=O)-N(R ^1b )-The compound of claim 55, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 59)
XY is -CH ₂ N(R ^1c )-CH ₂ -The compound according to item 55, which is -, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 60)
XY is -C(=O)N(R ^1d )-CH ₂ -The compound according to item 55, which is -, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 61)
XY is -CH ₂ CH ₂ -N(R ^1e )-The compound of claim 55, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 62)
XY is -CH ₂ N(R ^1f )-C(=O)-, or a compound thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 63)
XY is -CH ₂ O-CH ₂ -The compound according to item 55, which is -, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 64)
The compound according to any one of items 1 to 54, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein X and Y do not form a chemical bond and X is hydrogen.
(Item 65)
Y is cyano and -CH ₂ -R ¹² 65. The compound according to item 64, or a pharmaceutically acceptable salt, hydrate or solvate thereof, which is selected from the group consisting of:
(Item 66)
65. The compound according to item 65, wherein Y is cyano, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 67)
Y is -CH ₂ -R ¹² 65. The compound according to item 65, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 68)
The compound of item 53, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, having formula IX:

In the formula,
XY is -CH ₂ N(R ^1c )-CH ₂ -Or
X and Y do not form a chemical bond,
X is hydrogen; and
Y is -CN and -CH ₂ -R ¹² Selected from the group consisting of;
R ^1c Is C _{1 to 3} Alkyl;
R ¹² Is selected from the group consisting of amino and heteroaryl;
R ^17a Is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl;
R ¹⁸ Is -OC(=O)-amino and -NHC(=O)-R ^19b Selected from the group consisting of;
R ^19b Is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl.
(Item 69)
The following formula:

The compound according to item 68, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, comprising any one or more of:
(Item 70)
XY is -CH ₂ N(R ^1c )-CH ₂ -Is;
R ^1c But hydrogen and C _{1 to 6} Selected from the group consisting of alkyl,
A compound according to item 68 or 69, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 71)
The compound of item 68, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, having the formula Xi:

In the formula,
Y is cyano and -CH ₂ -R ¹² Selected from the group consisting of;
R ¹² Is selected from the group consisting of amino and heteroaryl;
R ^17a Is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl;
R ^17b And R ^17c Are independently selected from the group consisting of hydrogen and halo;
R ¹⁸ Is -OC(=O)-amino and -NHC(=O)-R ^19b Selected from the group consisting of;
R ^19b Is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ^{twenty four} Is selected from the group consisting of hydrogen and fluoro.
(Item 72)
The following formula:

72. The compound according to item 71, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, comprising any one or more of:
(Item 73)
A compound according to item 1, selected from one or more compounds according to Table 1, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
(Item 74)
A compound according to item 73, or a pharmaceutically acceptable salt, hydrate or solvate thereof, selected from one or more compounds according to table 2 or table 5.
(Item 75)
A pharmaceutical composition comprising a compound according to any one of items 1 to 74, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier.
(Item 76)
A method for treating a patient having cancer, a chronic autoimmune disorder, an inflammatory condition, a proliferative disorder, sepsis, or a viral infection, wherein the patient has the compound according to any one of items 1-74. Or administering a therapeutically effective amount of a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 77)
The method according to item 76, wherein the patient has cancer.
(Item 78)
Cancer is adrenal gland cancer, acinar cell carcinoma, acoustic neuroma, acrosome melanoma, apical sweat adenoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblast Leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue tumor, adrenocortical carcinoma, Adult T cell leukemia/lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft tissue sarcoma, ameloblastic fibroma, undifferentiated large cell lymphoma, undifferentiated thyroid cancer, angioimmunoblast T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid/rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cells Cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, melanoma, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementum Tumor, myelosarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, renal clear cell sarcoma, craniopharyngioma, cutaneous T cell lymphoma, cervical cancer, colorectal cancer, degos disease, fibrogenic Small round cell tumor, diffuse large B-cell lymphoma, embryonal dysplastic neuroepithelial tumor, anaplastic germinoma, fetal cancer, endocrine tumor, yolk sac tumor, enteropathy-related T-cell lymphoma, esophagus Cancer, encapsulated malformation fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglionoma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, bone giant Cell tumor, glial tumor, glioblastoma multiforme, glioma, cerebral glioma, glucagonoma, gonadal blastoma, granulosa cell tumor, semi-negative ovarian tumor, gallbladder cancer, gastric cancer, Hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, invasive lobular cancer, intestinal cancer, kidney Cancer, laryngeal cancer, malignant lentigo, lethal midline cancer, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute bone marrow Leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral schwannoma, malignant Triton tumor, mantle cell lymphoma, marginal zone B Cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, breast medulla carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma , Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, Mullerian mixed tumor, mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoliposarcoma, myxoma, mucus Sarcoma, nasopharyngeal cancer, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath Meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, Pituitary adenoma, Pituitary tumor, Plasmacytoma, Multiembryonal tumor, Precursor T lymphoblastic lymphoma, Primary CNS lymphoma, Primary exudative lymphoma, Primary peritoneal cancer, Prostate cancer, Pancreatic cancer , Pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcoma, schwannoma, Seminoma, Sertoli cell tumor, gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot warts, spinal tumor, Splenic marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary, small intestine cancer, squamous carcinoma, gastric cancer, T cell lymphoma, testicular cancer, capsular cell tumor, Thyroid cancer, transitional cell cancer, throat cancer, allantoic cancer, genitourinary cancer, urothelial cancer, uveal melanoma, uterine cancer, warts cancer, visual pathway glioma, vulva The method according to item 77, which is selected from the group consisting of cancer, vaginal cancer, Waldenstrom macroglobulinemia, Wartin tumor, and Wilms tumor.
(Item 79)
Cancer is acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer (SCLC), neuroblast Item 77. The method according to Item 77, which is selected from the group consisting of cell tumor, Burkitt lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.
(Item 80)
80. The method of any of paragraphs 76-79, further comprising administering a therapeutically effective amount of a second therapeutic agent useful in treating the disease or condition.
(Item 81)
A pharmaceutical composition according to item 75, for use in the treatment of cancer, chronic autoimmune disorders, inflammatory conditions, proliferative disorders, sepsis, or viral infections.
(Item 82)
A pharmaceutical composition according to item 81, for use in the treatment of cancer.
(Item 83)
Cancer is adrenal gland cancer, acinar cell carcinoma, acoustic neuroma, acrosome melanoma, apical sweat adenoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblast Leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue tumor, adrenocortical carcinoma, Adult T cell leukemia/lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft tissue sarcoma, ameloblastic fibroma, undifferentiated large cell lymphoma, undifferentiated thyroid cancer, angioimmunoblast T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid/rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cells Cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, melanoma, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementum Tumor, myelosarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, renal clear cell sarcoma, craniopharyngioma, cutaneous T cell lymphoma, cervical cancer, colorectal cancer, degos disease, fibrogenic Small round cell tumor, diffuse large B-cell lymphoma, embryonal dysplastic neuroepithelial tumor, anaplastic germinoma, fetal cancer, endocrine tumor, yolk sac tumor, enteropathy-related T-cell lymphoma, esophagus Cancer, encapsulated malformation fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglionoma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, bone giant Cell tumor, glial tumor, glioblastoma multiforme, glioma, cerebral glioma, glucagonoma, gonadal blastoma, granulosa cell tumor, semi-negative ovarian tumor, gallbladder cancer, gastric cancer, Hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, invasive lobular cancer, intestinal cancer, kidney Cancer, laryngeal cancer, malignant lentigo, lethal midline cancer, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute bone marrow Leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral schwannoma, malignant Triton tumor, mantle cell lymphoma, marginal zone B Cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, breast medulla carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma , Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, Mullerian mixed tumor, mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoliposarcoma, myxoma, mucus Sarcoma, nasopharyngeal cancer, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath Meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, Pituitary adenoma, Pituitary tumor, Plasmacytoma, Polyembryonal tumor, Precursor T lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary exudative lymphoma, Primary peritoneal cancer, Prostate cancer, Pancreatic cancer , Pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcoma, schwannoma, Seminoma, Sertoli cell tumor, gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot warts, spinal tumor, Marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, gastric cancer, T cell lymphoma, testicular cancer, capsular cell tumor, Thyroid cancer, transitional cell cancer, throat cancer, allantoic cancer, genitourinary cancer, urothelial cancer, uveal melanoma, uterine cancer, warts cancer, visual pathway glioma, vulva 83. The pharmaceutical composition according to item 82, which is selected from the group consisting of cancer, vaginal cancer, Waldenstrom macroglobulinemia, Wartin tumor, and Wilms tumor.
(Item 84)
Cancer is acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer (SCLC), neuroblastoma 83. The pharmaceutical composition according to item 82, which is selected from the group consisting of cell tumor, Burkitt lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.
(Item 85)
A compound according to any one of paragraphs 1-74, or a pharmaceutically acceptable compound, for use in the treatment of cancer, chronic autoimmune disorders, inflammatory conditions, proliferative disorders, sepsis, or viral infections. A salt, hydrate or solvate thereof.
(Item 86)
85. A compound according to item 85, for use in the treatment of cancer.
(Item 87)
Cancer is adrenal gland cancer, acinar cell carcinoma, acoustic neuroma, acrosome melanoma, apical sweat adenoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblast Leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue tumor, adrenocortical carcinoma, Adult T cell leukemia/lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft tissue sarcoma, ameloblastic fibroma, undifferentiated large cell lymphoma, undifferentiated thyroid cancer, angioimmunoblast T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid/rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cells Cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, melanoma, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementum Tumor, myelosarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, renal clear cell sarcoma, craniopharyngioma, cutaneous T cell lymphoma, cervical cancer, colorectal cancer, degos disease, fibrogenic Small round cell tumor, diffuse large B-cell lymphoma, embryonal dysplastic neuroepithelial tumor, anaplastic germinoma, fetal cancer, endocrine tumor, yolk sac tumor, enteropathy-related T-cell lymphoma, esophagus Cancer, encapsulated malformation fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglionoma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, bone giant Cell tumor, glial tumor, glioblastoma multiforme, glioma, cerebral glioma, glucagonoma, gonadal blastoma, granulosa cell tumor, semi-negative ovarian tumor, gallbladder cancer, gastric cancer, Hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, invasive lobular cancer, intestinal cancer, kidney Cancer, laryngeal cancer, malignant lentigo, lethal midline cancer, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute bone marrow Leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral schwannoma, malignant Triton tumor, mantle cell lymphoma, marginal zone B Cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, breast medulla carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma , Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, Mullerian mixed tumor, mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoliposarcoma, myxoma, mucus Sarcoma, nasopharyngeal cancer, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath Meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, Pituitary adenoma, Pituitary tumor, Plasmacytoma, Polyembryonal tumor, Precursor T lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary exudative lymphoma, Primary peritoneal cancer, Prostate cancer, Pancreatic cancer , Pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcoma, schwannoma, Seminoma, Sertoli cell tumor, gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot warts, spinal tumor, Marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, gastric cancer, T cell lymphoma, testicular cancer, capsular cell tumor, Thyroid cancer, transitional cell cancer, throat cancer, allantoic cancer, genitourinary cancer, urothelial cancer, uveal melanoma, uterine cancer, warts cancer, visual pathway glioma, vulva The compound according to item 86, which is selected from the group consisting of cancer, vaginal cancer, Waldenstrom macroglobulinemia, Wartin tumor, and Wilms tumor.
(Item 88)
Cancer is acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer (SCLC), neuroblast 89. The compound according to item 86, which is selected from the group consisting of cell tumor, Burkitt lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.
(Item 89)
A compound according to any one of paragraphs 1-74, or a pharmaceutically compound, for the manufacture of a medicament for the treatment of cancer, chronic autoimmune disorders, inflammatory conditions, proliferative disorders, sepsis, or viral infections. Use of an acceptable salt, hydrate or solvate thereof.
(Item 90)
Use according to item 89 for the treatment of cancer.
(Item 91)
Cancer is adrenal gland cancer, acinar cell carcinoma, acoustic neuroma, acrosome melanoma, apical sweat adenoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblast Leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue tumor, adrenocortical carcinoma, Adult T cell leukemia/lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft tissue sarcoma, ameloblastic fibroma, undifferentiated large cell lymphoma, undifferentiated thyroid cancer, angioimmunoblast T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid/rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cells Cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, melanoma, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementum Tumor, myelosarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, renal clear cell sarcoma, craniopharyngioma, cutaneous T cell lymphoma, cervical cancer, colorectal cancer, degos disease, fibrogenic Small round cell tumor, diffuse large B-cell lymphoma, embryonal dysplastic neuroepithelial tumor, anaplastic germinoma, fetal cancer, endocrine tumor, yolk sac tumor, enteropathy-related T-cell lymphoma, esophagus Cancer, encapsulated malformation fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglionoma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, bone giant Cell tumor, glial tumor, glioblastoma multiforme, glioma, cerebral glioma, glucagonoma, gonadal blastoma, granulosa cell tumor, semi-negative ovarian tumor, gallbladder cancer, gastric cancer, Hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, invasive lobular cancer, intestinal cancer, kidney Cancer, laryngeal cancer, malignant lentigo, lethal midline cancer, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute bone marrow Leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral schwannoma, malignant Triton tumor, mantle cell lymphoma, marginal zone B Cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, breast medulla carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma , Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, Mullerian mixed tumor, mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoliposarcoma, myxoma, mucus Sarcoma, nasopharyngeal cancer, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath Meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, Pituitary adenoma, Pituitary tumor, Plasmacytoma, Polyembryonal tumor, Precursor T lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary exudative lymphoma, Primary peritoneal cancer, Prostate cancer, Pancreatic cancer , Pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcoma, schwannoma, Seminoma, Sertoli cell tumor, gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot warts, spinal tumor, Marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, gastric cancer, T cell lymphoma, testicular cancer, capsular cell tumor, Thyroid cancer, transitional cell carcinoma, throat cancer, allantoic carcinoma, genitourinary cancer, urothelial cancer, uveal melanoma, uterine cancer, verrucous cancer, visual pathway glioma, vulva The use according to item 90, which is selected from the group consisting of cancer, vaginal cancer, Waldenstrom macroglobulinemia, Wartin tumor, and Wilms tumor.
(Item 92)
Cancer is acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer (SCLC), neuroblastoma 90. The use according to item 90, which is selected from the group consisting of cell tumor, Burkitt lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.
(Item 93)
The compound according to any one of items 1 to 74, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and cancer, chronic autoimmune disorder, inflammatory condition, proliferative disorder, sepsis , Or a patient with a viral infection and instructions for administering the compound, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
(Item 94)
The kit according to item 93, wherein the patient has cancer.
(Item 95)
Cancer is adrenal gland cancer, acinar cell carcinoma, acoustic neuroma, acrosome melanoma, apical sweat adenoma, acute eosinophilic leukemia, acute erythroid leukemia, acute lymphoblastic leukemia, acute megakaryoblast Leukemia, acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenoid odontogenic tumor, adenosquamous cell carcinoma, adipose tissue tumor, adrenocortical carcinoma, Adult T cell leukemia/lymphoma, aggressive NK cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft tissue sarcoma, ameloblastic fibroma, undifferentiated large cell lymphoma, undifferentiated thyroid cancer, angioimmunoblast T-cell lymphoma, angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid/rhabdoid tumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, B-cell lymphoma, basal cells Cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, Brenner tumor, melanoma, Burkitt lymphoma, breast cancer, brain cancer, carcinoma, carcinoma in situ, carcinosarcoma, cartilage tumor, cementum Tumor, myelosarcoma, chondroma, chordoma, choriocarcinoma, choroid plexus papilloma, renal clear cell sarcoma, craniopharyngioma, cutaneous T cell lymphoma, cervical cancer, colorectal cancer, degos disease, fibrogenic Small round cell tumor, diffuse large B-cell lymphoma, embryonal dysplastic neuroepithelial tumor, anaplastic germinoma, fetal cancer, endocrine tumor, yolk sac tumor, enteropathy-related T-cell lymphoma, esophagus Cancer, encapsulated malformation fetus, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroid cancer, ganglionoma, gastrointestinal cancer, germ cell tumor, gestational choriocarcinoma, giant cell fibroblastoma, bone giant Cell tumor, glial tumor, glioblastoma multiforme, glioma, cerebral glioma, glucagonoma, gonadal blastoma, granulosa cell tumor, semi-negative ovarian tumor, gallbladder cancer, gastric cancer, Hairy cell leukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma, hematological malignancies, hepatoblastoma, hepatosplenic T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, invasive lobular cancer, intestinal cancer, kidney Cancer, laryngeal cancer, malignant lentigo, lethal midline cancer, leukemia, Leydig cell tumor, liposarcoma, lung cancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma, acute lymphocytic leukemia, acute bone marrow Leukemia, chronic lymphocytic leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, MALT lymphoma, malignant fibrous histiocytoma, malignant peripheral schwannoma, malignant Triton tumor, mantle cell lymphoma, marginal zone B Cell lymphoma, mast cell leukemia, mediastinal germ cell tumor, breast medulla carcinoma, medullary thyroid carcinoma, medulloblastoma, melanoma, meningioma , Merkel cell carcinoma, mesothelioma, metastatic urothelial carcinoma, Mullerian mixed tumor, mucinous tumor, multiple myeloma, muscle tissue tumor, mycosis fungoides, myxoliposarcoma, myxoma, mucus Sarcoma, nasopharyngeal cancer, schwannoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, eye cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath Meningioma, optic nerve tumor, oral cancer, osteosarcoma, ovarian cancer, pancoast tumor, papillary thyroid cancer, paraganglioma, pineoblastoma, pineocytoma, pituitary cell tumor, Pituitary adenoma, Pituitary tumor, Plasmacytoma, Polyembryonal tumor, Precursor T lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary exudative lymphoma, Primary peritoneal cancer, Prostate cancer, Pancreatic cancer , Pharyngeal cancer, peritoneal pseudomyxoma, renal cell carcinoma, renal medullary carcinoma, retinoblastoma, rhabdomyomas, rhabdomyosarcoma, Richter transformation, rectal cancer, sarcoma, schwannoma, Seminoma, Sertoli cell tumor, gonadal stromal tumor, signet ring cell carcinoma, skin cancer, small blue round cell tumor, small cell carcinoma, soft tissue sarcoma, somatostatinoma, soot warts, spinal tumor, Marginal zone lymphoma, squamous cell carcinoma, synovial sarcoma, Sezary's disease, small intestine cancer, squamous carcinoma, gastric cancer, T cell lymphoma, testicular cancer, capsular cell tumor, Thyroid cancer, transitional cell cancer, throat cancer, allantoic cancer, genitourinary cancer, urothelial cancer, uveal melanoma, uterine cancer, warts cancer, visual pathway glioma, vulva The kit according to Item 94, which is selected from the group consisting of cancer, vaginal cancer, Waldenstrom macroglobulinemia, Wartin tumor, and Wilms tumor.
(Item 96)
Cancer is acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed leukemia, NUT midline cancer, multiple myeloma, small cell lung cancer (SCLC), neuroblastoma 94. The kit according to item 94, which is selected from the group consisting of cell tumor, Burkitt lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.
(Item 97)
The kit of any one of paragraphs 93-96, further comprising one or more additional therapeutic agents.

Claims (33)

Having the formula VIi, of compound or a pharmaceutically acceptable salt, hydrate or solvate thereof:

In the formula,
XY is the following:
-N(R ^1a )-C(=O)-;
-C(=O)-O-;
-C(=O)-N(R ^1b )-;
-CH ₂ N(R ^1c )-CH ₂ -;
-C(=O)N(R ^1d )-CH ₂ -;
-CH ₂ CH ₂ -N(R ^1e )-;
-CH ₂ N(R ^1f )-C(=O)-; and
-CH ₂ O-CH ₂ -
Is selected from the group consisting of; or
R ^1a is selected from the group consisting of hydrogen and alkyl;
R ^1b is selected from the group consisting of hydrogen, alkyl, and aralkyl;
R ^1c is hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclo, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, aralkyl, (heteroaryl)alkyl, alkylcarbonyl Selected from the group consisting of:, arylcarbonyl, and alkoxycarbonyl;
R ^1d is selected from the group consisting of hydrogen, alkyl, and aralkyl;
R ^1e is selected from the group consisting of hydrogen, alkyl, and (aryloxy)alkyl;
R ^1f is selected from the group consisting of hydrogen and alkyl;
R ² is hydrogen, alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted heteroaryl, and aralkyl. Selected;
R ^3a and R ^3b are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ^17a is hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, (cycloalkyl)alkylsulfonyl, arylsulfonyl, hetero. Selected from the group consisting of arylsulfonyl, heterocyclosulfonyl, sulfonamide, optionally substituted heteroaryl, optionally substituted heterocyclo, carboxamide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, carboxy, and carboxyalkyl;
R ^17b and R ^17c are independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy. R ^17a is selected from the group consisting of alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl; and
R ^17b and R ^17c are hydrogen,
2. The compound according to claim 1 , or a pharmaceutically acceptable salt, hydrate or solvate thereof. R ² is selected from the group consisting of alkyl, alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, optionally substituted heteroaryl, and aralkyl. The compound according to claim 1 or 2 , or a pharmaceutically acceptable salt, hydrate or solvate thereof. 4. The compound according to claim 3 , wherein R ² is unsubstituted cycloalkyl, or a pharmaceutically acceptable salt, hydrate or solvate thereof. The compound of claim 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein R ² is a substituted cycloalkyl having the formula VII:

In the formula,
R ¹⁸ is halo, nitro, cyano, hydroxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamide, sulfonamide, alkylcarbonyl, aryl. Carbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl Optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, (heterocyclo)alkyl, -OC(=O)-amino, -N(R ^19a )C(=O)-R ^19b , And -N(R ^20a )SO ₂ -R ^20b ;
R ^19a is selected from the group consisting of hydrogen and alkyl;
R ^19b is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ^20a is selected from the group consisting of hydrogen and alkyl;
R ^20b is selected from the group consisting of amino, alkyl, and optionally substituted aryl. The compound according to claim 5 , or a pharmaceutically acceptable salt or hydrate thereof, wherein R ¹⁸ is selected from the group consisting of -OC(=O)-amino and -NHC(=O)-R ^19b. Or a solvate. R ² is a group consisting of:



4. The compound of claim 3 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which is selected from the following, wherein “*” indicates a point of attachment to the rest of the molecule. XY is -N(R ^1a )-C(=O)-, -C(=O)-O-, -C(=O)-N(R ^1b )-, -CH ₂ N(R ^1c )- CH ₂ -, -C(=O)N(R ^1d )-CH ₂ -, -CH ₂ CH ₂ -N(R ^1e )-, -CH ₂ N(R ^1f )-C(=O)-, and -CH ₂ O-CH ₂ - is selected from the group consisting of the compound of any one of claims 1-7, or a pharmaceutically acceptable salt, hydrate or solvate thereof. 9. The compound according to claim 8 , wherein XY is —CH ₂ N(R ^1c )—CH ₂ —, or a pharmaceutically acceptable salt, hydrate or solvate thereof. 9. The compound according to claim 8 , wherein XY is —CH ₂ CH ₂ —N(R ^1e )—, or a pharmaceutically acceptable salt, hydrate or solvate thereof. 9. The compound according to claim 8 , wherein XY is -CH ₂ N(R ^1f )-C(=O)-, or a pharmaceutically acceptable salt, hydrate or solvate thereof. 9. The compound according to claim 8 , wherein XY is —CH ₂ O—CH ₂ —, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Having the formula IX, the compounds of claim 1, wherein or a pharmaceutically acceptable salt, hydrate or solvate thereof:

In the formula,
XY is ^{_{-CH 2 N (R 1c) -CH}} 2 - Ri der;
R ^1c is C _1-3 alkyl ;
R ^17a is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl;
R ¹⁸ is selected from the group consisting of -OC(=O)-amino and -NHC(=O)-R ^19b ;
R ^19b is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl. XY is -CH ₂ N(R ^1c )-CH ₂ -;
R ^1c is selected from the group consisting of hydrogen and C _1-6 alkyl,
2. The compound according to claim 1 , or a pharmaceutically acceptable salt, hydrate or solvate thereof. A compound having formula X, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:

In the formula,
Y is selected from the group consisting of cyano, hydroxy and -CH ₂ -R ^12;
R ^3a and R ^3b are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ¹² is selected from the group consisting of hydroxy, amino, optionally substituted heteroaryl, optionally substituted heterocyclo and --NHC(═O)--R ¹⁶ .
R ¹⁶ is selected from the group consisting of alkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted cycloalkyl;
R ^17a is hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, (cycloalkyl)alkylsulfonyl, arylsulfonyl, hetero. Selected from the group consisting of arylsulfonyl, heterocyclosulfonyl, sulfonamide, optionally substituted heteroaryl, optionally substituted heterocyclo, carboxamide, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, carboxy, and carboxyalkyl;
R ¹⁸ is halo, nitro, cyano, hydroxy, alkylcarbonyloxy, cycloalkylcarbonyloxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamide, sulfonamide, alkylcarbonyl, aryl. Carbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, optionally substituted alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl Optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, (heterocyclo)alkyl, -OC(=O)-amino, -N(R ^19a )C(=O)-R ^19b , And -N(R ^20a )SO ₂ -R ^20b ;
R ^19a is selected from the group consisting of hydrogen and alkyl;
R ^19b is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ^20a is selected from the group consisting of hydrogen and alkyl;
R ^20b is selected from the group consisting of amino, alkyl, and optionally substituted aryl. Y is -CH ₂ -R ¹² 16. The compound of claim 15, which is: or a pharmaceutically acceptable salt, hydrate, or solvate thereof. R ¹² 17. The compound according to claim 16, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is a 5-membered heteroaryl. R ¹² Is an optionally substituted imidazol-1-yl, The compound of claim 16, or a pharmaceutically acceptable salt, hydrate or solvate thereof. R ¹² is

19. The compound of claim 18, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Y is cyano and -CH ₂ -R ¹² Selected from the group consisting of;
R ¹² Is selected from the group consisting of amino and heteroaryl;
R ^17a Is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl;
R ¹⁸ Is -OC(=O)-amino and -NHC(=O)-R ^19b Selected from the group consisting of;
R ^19b 16. The compound of claim 15 selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl, or a pharmaceutically acceptable salt, hydrate, or solvate thereof. Having the formula Xi, of compound or a pharmaceutically acceptable salt, hydrate or solvate thereof:

In the formula,
Y is selected from the group consisting of cyano and -CH ₂ -R ^12;
R ^3a and R ^3b are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ¹² is selected from the group consisting of amino and heteroaryl;
R ^17a is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, and heteroarylsulfonyl;
R ^17b and R ^17c are independently selected from the group consisting of hydrogen and halo;
R ¹⁸ is selected from the group consisting of -OC(=O)-amino and -NHC(=O)-R ^19b ;
R ^19b is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ²⁴ is selected from the group consisting of hydrogen and fluoro. A compound having formula Xi, or a pharmaceutically acceptable salt, hydrate, or solvate thereof:

In the formula,
Y is selected from the group consisting of cyano and -CH ₂ -R ^12;
R ^3a and R ^3b are each independently selected from the group consisting of hydrogen, alkyl, halo, hydroxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkoxy, and haloalkoxy;
R ¹² is an optionally substituted 5-membered ring heteroaryl;
R ^17a is selected from the group consisting of chloro, cyano, alkylsulfonyl, haloalkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl and heteroarylsulfonyl;
R ^17b and R ^17c are independently selected from the group consisting of hydrogen and halo;
R ¹⁸ is selected from the group consisting of -OC(=O)-amino and -NHC(=O)-R ^19b ;
R ^19b is selected from the group consisting of amino, alkoxy, alkyl, and optionally substituted aryl;
R ²⁴ is selected from the group consisting of hydrogen and fluoro. R ¹² 23. The compound of claim 22, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is imidazol-1-yl, which may be substituted. R ¹² 23. The compound of claim 22, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is an optionally substituted 1,3,4-triazole. R ¹² 23. The compound of claim 22, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein is an optionally substituted 1,2,3-triazole. The following formula:

The compound according to any one of claims 21 to 25 , or a pharmaceutically acceptable salt, hydrate, or solvate thereof, comprising any one or more of the above.
One or selected from a plurality of compounds, of compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, of.
One or selected from a plurality of compounds, of compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, of. The compound of any one of claims 1 to 28, or a pharmaceutically acceptable salt, hydrates or solvates, and a pharmaceutically acceptable carrier, a pharmaceutical composition. 30. The pharmaceutical composition according to claim 29 , for use in the treatment of cancer, chronic autoimmune disorders, inflammatory conditions, proliferative disorders, sepsis, or viral infections. Cancer, acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia is selected from chronic lymphocytic leukemia, and mixed leukemia or Ranaru group claim 30 pharmaceutical composition. A compound according to any one of claims 1 to 28 , or a pharmaceutical, for the manufacture of a medicament for the treatment of cancer, chronic autoimmune disorders, inflammatory conditions, proliferative disorders, sepsis, or viral infections. Use of a salt, hydrate, or solvate thereof that is acceptable to. Cancer, acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia is selected from chronic lymphocytic leukemia, and mixed leukemia or Ranaru group, Use according to claim 32, wherein.